

> O <
O | O IntelliGenetics
> O <

Quest - Quick User-directed Expression Search Tool
Release 5.4

-- Outline of search "claimlags_len7" --
Selected search type is key against sequence data banks or files.
Selected scope is Sequence.

Selected sequence key from "salvoza029.key":

claim1 (AA) ID claim1 AA preliminary pattern

1 followed by

2 any character except d or e or k or r or h from 0 to 1 times

2 any character except k or r or h from 0 to 1 times

2 any character except d or e

2 w

2 any character except a or l or i

2 a or v or l or i or p or f or w or m or c

2 k or r or h

2 k or r or h

2 any character except d or e or g or s or t or y or n or q

2 any character except d or e or g or s or t or y or n or q from 0 to 1 times

Selected files:

File : claimlags_len7.pep

-- Output Parameters --

Format Options:
Nucleic acid code matching Exact Indirect file No
Find non-matching hits only No Sequence or key file No
Report key used Yes List of hits Yes
Note position of hit Yes Hit display Yes
Display full annotations Yes Name and annotations Yes
Sequence context 50

-- Run Parameters --

Run mode Batch
Time to start comparison now
Notify at end of run No

2 matches found in sequence:

aaw48275 ; Rat ninjurin peptide.

(from "claimlags_len7.pep")

TOIG of: aaw48275 Check: 2225 from: 1 to: 7

>>>AAW48275

ID AAW48275 standard; peptide; 7 AA.

XX AC AAW48275;

XX AC AAW48275;

XX DT 23-JUN-1998 (first entry)

XX DT Rat ninjurin peptide.

XX DE Rat; ninjurin; cellular adhesion molecule; membrane bound; tumour;

XX KW nerve injury induced gene; inflammation; nervous system.

XX KW nerve injury induced gene; inflammation; nervous system.

XX OS Rattus sp.

XX OS Rattus sp.

XX PN WO9803650-A1.

XX PN WO9803650-A1.

XX PD 29-JAN-1998.

XX PD 29-JAN-1998.

XX XX 24-JUL-1997; 97WO-US012210.

XX XX 24-JUL-1997; 97WO-US012210.

XX XX 24-JUL-1996; 96US-00672850.

XX XX 24-JUL-1996; 96US-00672850.

XX PR

XX (UNIW) UNIV WASHINGTON.

XX PI Milbrandt J, Araki T;

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX XX WPI; 1998-120775/11.

XX The present sequence represents a rat ninjurin (nerve injury induced)
XX peptide. The ninjurin protein (NP) plays a role in axonal regeneration of
XX peripheral nervous system (PNS) neuronal cells after injury. The products
XX can be used for developing products for treating ninjurin mediated
XX disorders including conditions involving inappropriate (i.e. excessive or
XX insufficient) cellular adhesion. Conditions involving excessive cellular
XX adhesion which may be treated include e.g. inflammatory diseases such as
XX rheumatoid arthritis, asthma, allergy conditions, adult respiratory
XX distress syndrome, inflammatory bowel diseases (e.g. Crohn's disease,
XX ulcerative colitis and regional enteritis) and ophthalmic inflammatory
XX diseases, autoimmune diseases, thrombosis or inappropriate platelet
XX aggregation conditions, arteriosclerosis, reocclusion following
XX thrombolysis, cardiovascular diseases, some forms of diabetes and
XX neoplastic disease including metastasis conditions. The products can also
XX be used to promote cellular adhesion, e.g. in nerve regeneration, wound
XX healing or prosthetic implantation. The products can also be used for
XX detection, purification, diagnosis and screening assays

Claim 20; Page 56; 80pp; English.

Sequence 7 AA; (salvoza029.key)

Found using 'claim1' (salvoza029.key)

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

XX The present sequence represents a rat ninjurin (nerve injury induced)
XX peptide. The ninjurin protein (NP) plays a role in axonal regeneration of
XX peripheral nervous system (PNS) neuronal cells after injury. The products
XX can be used for developing products for treating ninjurin mediated
XX disorders including conditions involving inappropriate (i.e. excessive or
XX insufficient) cellular adhesion. Conditions involving excessive cellular
XX adhesion which may be treated include e.g. inflammatory diseases such as
XX rheumatoid arthritis, asthma, allergy conditions, adult respiratory
XX distress syndrome, inflammatory bowel diseases (e.g. Crohn's disease,
XX ulcerative colitis and regional enteritis) and ophthalmic inflammatory
XX diseases, autoimmune diseases, thrombosis or inappropriate platelet
XX aggregation conditions, arteriosclerosis, reocclusion following
XX thrombolysis, cardiovascular diseases, some forms of diabetes and
XX neoplastic disease including metastasis conditions. The products can also
XX be used to promote cellular adhesion, e.g. in nerve regeneration, wound
XX healing or prosthetic implantation. The products can also be used for
XX detection, purification, diagnosis and screening assays

Claim 20; Page 56; 80pp; English.

Sequence 7 AA; (salvoza029.key)

Found using 'claim1' (salvoza029.key)

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

1 1 6 7

